The company reported revenues of $490.2 million, up from $443.7 million in Q2 2018 and beating the consensus Wall Street estimate of $477.8 million.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
Startup healthcare analytics company Progknowse will work with hospitals and sequencing labs to build a clinical and genomic dataset.
With whole-genome sequences and other analyses, researchers delved into drug resistance and more in 600 staphylococcus isolates from high-touch surfaces in East and West London.
The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."
Researchers used exome sequences on almost 550 canine transmissible venereal tumors to estimate their origin, global spread, and evolution.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
The deals follow a pair of other recent acquisitions by Precision for Medicine in the artificial intelligence technology and biomarker analysis fields.
The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.
The regulatory approval means that the assay for minimal residual disease is available to monitor B cell blood cancers in patients in all 50 states.
The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.
Product and service revenues were up 10 percent year over year to $22.4 million compared to $20.4 million in the year-ago quarter.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
Through a transcriptomic analysis, the researchers developed a catalog of gene expression with the olfactory mucosa of half a dozen mammals.
The partners will request samples from more than 2,500 existing and new participants in the foundation's Preeclampsia Registry for sequencing analysis.
With exome sequences for tens of thousands of Finns, researchers identified deleterious variants linked to dozens of clinically relevant quantitative traits.
The new company, whose name was not disclosed, will provide preclinical and clinical immune monitoring and biomarker services to biopharma companies.
The company also reported higher operating costs as it worked to develop and validate its Parsortix circulating tumor cell collection system for clinical use.
Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.
Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
The partners are working under NIAAA grants to identify genetic markers to help predict response to the drug acamprosate, which is used as a treatment for alcoholism.
An international team documented TP53 mutation-related genomic changes across dozens of cancer types using data generated with five platforms for the Cancer Genome Atlas project.
The deal covers Curetis' Unyvero A50 instrument system and test cartridges, and builds on a separate distribution agreement the company recently signed.
The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.